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Cellular senescence suppresses cancer by halting
the growth of premalignant cells, yet the accumula-
tion of senescent cells is thought to drive age-related
pathology through a senescence-associated secre-
tory phenotype (SASP), the function of which is
unclear. To understand the physiological role(s) of
the complex senescent phenotype, we generated
a mouse model in which senescent cells can be
visualized and eliminated in living animals. We
show that senescent fibroblasts and endothelial cells
appear very early in response to a cutaneous wound,
where they accelerate wound closure by inducing
myofibroblast differentiation through the secretion
of platelet-derived growth factor AA (PDGF-AA).
In two mouse models, topical treatment of senes-
cence-free wounds with recombinant PDGF-AA
rescued the delayed wound closure and lack of
myofibroblast differentiation. These findings define
a beneficial role for the SASP in tissue repair and
help to explain why the SASP evolved.
INTRODUCTION
Cellular senescence is a complex stress response whereby
cells that are capable of proliferation lose this ability, essentially
irreversibly (Campisi, 2013). Since its formal description >50722 Developmental Cell 31, 722–733, December 22, 2014 ª2014 Elsyears ago (Hayflick and Moorhead, 1961), the senescence
response has been implicated in two apparently disparate
processes: tumor suppression and aging. There is now sub-
stantial evidence that the senescence growth arrest is indeed
a formidable barrier to tumorigenesis, and mounting evi-
dence indicates that an accumulation of senescence cells
can drive phenotypes and pathologies associated with aging
(Campisi, 2013). Thus, cellular senescence is likely an example
of evolutionary antagonistic pleiotropy, being beneficial at
young ages but detrimental at older ages (Campisi, 2003). Se-
nescent cells most likely promote aging through their senes-
cence-associated secretory phenotype (SASP): the increased
expression and secretion of a suite of inflammatory cytokines,
chemokines, growth factors, and proteases (Coppé et al.,
2010a; van Deursen, 2014).
Although there are no strictly specific senescence markers,
most senescent cells express the tumor suppressor p16INK4a
(Ohtani et al., 2004), which prevents cell cycle progression
from the G1 to S phases by inhibiting two cycle-dependent
kinases, CDK4 and CDK6 (Sherr and Roberts, 1999). p16INK4a
also increases with age and is a robust senescence marker in
numerous mouse and human tissues (Krishnamurthy et al.,
2004; Ressler et al., 2006), often coinciding with another promi-
nent senescence marker, senescence-associated beta-galacto-
sidase (SA-b-gal) activity (Dimri et al., 1995). These and other
markers have been used to understand the causes and conse-
quences of cellular senescence in vivo.
Many stresses or stimuli induce a senescence response,
including aging, genomic or epigenomic damage, and tissue
injury. Senescent cells not only increase with age in multiple
tissues, they are also prominent at sites of several age-relatedevier Inc.
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limsky and Kurz, 2005), osteoarthritis (Martin and Buckwalter,
2003), chronic lung disease (Noureddine et al., 2011), and
precancerous lesions (Collado et al., 2007). The SASP is thought
to drive or exacerbate many of these pathologies. Recent
results show that life-long elimination of senescent cells can pre-
vent the development of certain age-related pathologies in a
mouse model of segmental accelerated aging, strongly support-
ing the idea that senescent cells can be deleterious (Baker et al.,
2011).
It remains unclear why senescent cells express a SASP given
its prominent inflammatory components and mostly detrimental
consequences (Freund et al., 2010). Of possible relevance
to this puzzle, senescent cells were recently detected during
embryogenesis, where they appear to play a nonessential role
in optimizing the development of certain embryonic structures
(Muñoz-Espı́n et al., 2013; Storer et al., 2013). Moreover, tissue
repair and wound healing are impaired in old individuals (Guo
and Dipietro, 2010), and the matrix metalloproteinases that
comprise the SASP (Coppé et al., 2008, 2010b) were proposed
to facilitate tissue repair by promoting collagen degradation,
thereby limiting fibrosis (Jun and Lau, 2010; Krizhanovsky
et al., 2008).
Tissue repair is an intricate process comprising four distinct
overlapping phases: (1) hemostasis, (2) inflammation, (3) prolif-
eration, and (4) remodeling. These phases are clearly evident
during wound healing in the skin. In this tissue, wound closure
occurs during the proliferation phase as a consequence of
wound contraction (Midwood et al., 2004), which is due pri-
marily to the formation of a newly synthesized granulation tis-
sue and induction of specialized contractile fibroblasts termed
myofibroblasts (Tomasek et al., 2002). Each phase is facili-
tated by soluble factors, some of which are known SASP
factors.
To more precisely assess the physiological role of senescent
cells in vivo, we created a mouse model (p16-3MR) in which
senescent cells can be detected in living animals, isolated from
tissues, and eliminated upon treatment with an otherwise inef-
fective drug. Here we show that senescent fibroblasts and endo-
thelial cells appear at wound sites a few days after skin injury.
These wound-associated senescent cells then promote optimal
wound healing by secreting PDGF-A, a SASP factor, which pro-
motes myofibroblast differentiation. These data support a posi-
tive role for senescent cells during tissue repair and help to
explain why the SASP evolved.
RESULTS
The p16-3MR Mouse Model
To identify, isolate, and selectively kill senescent cells, we
took advantage of the 3MR (trimodality reporter) fusion pro-
tein, which contains functional domains of a synthetic Renilla
luciferase (LUC), monomeric red fluorescent protein (mRFP),
and truncated herpes simplex virus 1 (HSV-1) thymidine kinase
(HSV-TK) (Ray et al., 2004) (Figure 1A). We chose as a
senescence-sensitive promoter that of the tumor suppressor
p16INK4a, which has been used to track senescent cells in other
mouse models (Baker et al., 2011; Burd et al., 2013; Yamakoshi
et al., 2009). We engineered a bacterial artificial chromosomeDevelopme(BAC) containing approximately 50 kb of the murine p16INK4a
locus such that the p16INK4a promoter drives 3MR expression.
We inactivated the p16INK4a and adjacent p19-Arf genes in the
BAC and created a transgenic mouse line (p16-3MR) containing
a single integrated copy of the engineered BAC. Thus, p16-3MR
mice are diploid for p16INK4a and p19-Arf. LUC allows the detec-
tion of 3MR-expressing cells by luminescence. mRFP permits
sorting of these cells from tissues, and HSV-TK allows their
killing by ganciclovir (GCV), a nucleoside analog that has a
high affinity for HSV-TK but low affinity for the cellular TK.
HSV-TK converts GCV into a toxic DNA chain terminator; in
nondividing senescent cells, GCV fragments mitochondrial
DNA, causing death by apoptosis (Laberge et al., 2013).
To verify 3MR transgene activity, we derived mouse embry-
onic fibroblasts (MEFs) from p16-3MR mice and induced
the cells to senesce using X irradiation (IR; 10 Gy). As ex-
pected, endogenous p16INK4a protein levels increased, peaking
10 days after IR (Figure S1A available online). We confirmed
senescence by decreased DNA synthesis, increased SA-b-gal
activity (Figure S1B), increased levels of mRNAs encoding
p16INK4a, p21, and the SASP factors interleukin-6 (IL-6) and
MMP-3, and decreased levels of the mRNA encoding laminB1
(Freund et al., 2012) (Figure 1B). Importantly, mRNA levels en-
coding the 3MR transgene (mRFP) and endogenous p16INK4a,
measured by quantitative PCR, behaved similarly (Figure 1B).
Further, senescent p16-3MR MEFs expressed mRFP by immu-
nostaining (Figures 1C and S1B), with a concomitant increase
in luciferase activity (Figure 1D). Finally, GCV selectively killed
senescent p16-3MR MEFs and showed no significant toxicity
in nonsenescent p16-3MR or wild-type (WT) cells (Figure 1E).
To verify that 3MR and endogenous p16INK4a were expressed
similarly in vivo, we exposed p16-3MR mice to 7 Gy full-body
IR. This IR dose is nonlethal but causes a persistent burden
of senescent cells, which are evident 3 months later (Le
et al., 2010). We treated the irradiated mice with GCV or PBS
(vehicle control) 90 days after IR. IR induced luminescence in
living animals (Figure 2A) and in isolated visceral fat, kidneys,
and lungs (Figure S2A). These tissues also showed increased
levels of mRNAs encoding p16INK4a, 3MR (mRFP), and the
SASP factors IL-6 and MMP-3, but not the non-SASP factor
IL-5 (Figures 2B, S2B, and S2C). Importantly, GCV treatment
of irradiated p16-3MR mice markedly reduced total body lumi-
nescence and senescence-associated gene expression, but
not IL-5 expression, in fat, kidneys and lungs (Figures 2A, 2B,
S2B, and S2C).
Senescent cells increase with age in many tissues (Campisi,
2013). p16-3MR mice showed a significant increase in lumi-
nescence starting 18 months of age (Figures S2D and
S2E). GCV treatment of old (20–24 months) mice efficiently
eliminated senescent cells as determined by reduced total
body luminescence (Figures 2C and S2E) and reduced lumi-
nescence, SA-b-gal staining, and p16INK4a mRNA levels in
biopsies of visceral fat (Figures 2D–2F). Notably, visceral fat
from young mice showed no difference in luminescence, SA-
b-gal, or p16INK4a mRNA levels upon GCV treatment (Figures
2D–2F).
Together, these findings show that p16-3MR transgenic mice
accurately report the presence of senescent cells through lumi-
nescence and allow their elimination by GCV.ntal Cell 31, 722–733, December 22, 2014 ª2014 Elsevier Inc. 723
Figure 1. Characterization of p16-3MR Cells
(A) Schematic of the p16-3MR transgene. See Results and Supplemental Experimental Procedures for details.
(B) qRT-PCR analysis of RNA isolated from nonsenescent (NS) and senescent (SEN; induced by 10 Gy IR) MEFs derived from p16-3MR embryos. RNA was
analyzed for mRNA levels of the indicated genes relative to actin mRNA (control for cDNA quantity) (n = 3 independent experiments; A.U., arbitrary units).
(C) Immunofluorescence of cells described in (B). Blue shows DAPI-stained nuclei; red shows mRFP immunostaining.
(D) Luminescencemeasurements of cells described in (B). Cells were incubated with coelentarazine and lysed, and luminescence intensity was quantified using a
luminometer (n = 3; A.U., arbitrary units).
(E) WT or p16-3MR MEFs were treated with GCV (10 mg/ml) for 7 days and evaluated for the percentage of surviving cells using the MTS assay (n = 4).
Data shown are the mean ± SD. **p < 0.01, ***p < 0.001.
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Wound Healing
Senescent stromal cells were shown to help resolve excessive
fibrosis after skin or liver injury (Jun and Lau, 2010; Krizhanovsky
et al., 2008). To directly assess the physiological consequences
of cellular senescence during tissue repair, we analyzed the abil-
ity of p16-3MR mice to heal cutaneous wounds.
We administered small full-thickness punch biopsies to the
dorsal flanks of p16-3MR mice. As reported by luminescence,
senescent cells were detected transiently at the injury site. In
young female p16-3MR animals, senescent cells were variable
2 days after wounding but significantly apparent 3 days after
wounding; senescent cells peaked 6 days after wounding
and then returned to barely detectable basal levels between 9
and 12 days after wounding (Figures 3A and 3B). Male animals
showed a similar transient induction of senescent cells but with
kinetics that were slower by 2–3 days, consistent with their
slower wound closure (Figure S3A). The induction of senes-
cence after wounding was confirmed by the presence of
RFP+ (by immunostaining using an anti-RFP antibody since
the fluorescent signal was lost after fixation) and SA-b-gal+ cells
in the wound gap (Figures 3C and S3B). The levels of mRNAs
encoding the senescence or SASP markers p16INK4a, mRFP,
p21, IL-1a, PAI-1, and vascular endothelial growth factor724 Developmental Cell 31, 722–733, December 22, 2014 ª2014 Els(VEGF) all increased and declined with kinetics similar to that
of luminescence (Figures 3D–3F and S3C), confirming the tran-
sient presence of senescent cells during the wound healing
process.
To determine the role of these transient senescent cells, we
wounded 3- to 4-month-old p16-3MR mice and treated them
with GCV 24 hours after injury. The effective elimination of senes-
cent cells by GCVwas confirmed by reduced luminescence (Fig-
ures 3A and 3B) and reduced mRNA levels encoding p16INK4a,
mRFP, and p21 at the injury site (Figures 3D–3F). Strikingly,
p16-3MR mice treated with GCV showed significantly delayed
kinetics of wound closure compared with vehicle-treated p16-
3MR or WT counterparts, with a peak delay at 6 days after
wounding (Figures 3G and 3H). This finding indicates that the
presence of senescent cells accelerates skin repair.
To independently confirm this finding, we analyzed p16INK4a/
p21 double knockout mice (p16/p21 DKO). Cells from single
p16INK4a or p21 KO mice are capable of senescence because
of compensatory activities of p16INK4a and p21; however, cells
from DKO mice show little or no senescence (Takeuchi et al.,
2010). Similar to our findings using GCV-treated p16-3MR
mice, p16/p21 DKO mice showed delayed wound healing
compared with WT counterparts (Figure 3I). Importantly, wound
healing in p16INK4a or p21 single knockout mice was similar toevier Inc.
Figure 2. Characterization of p16-3MR Mice
(A) Mock or IR p16-3MR mice, treated with vehicle (PBS) or 25 mg/kg of GCV for 5 days (daily i.p. injections; GCV), were injected with coelentarazine, and
luminescence was quantified using a Xenogen Imaging system.
(B) RNA was extracted from the fat of mice described in (A) and quantified by qRT-PCR for mRNA levels of endogenous p16INK4a, mRFP, IL-6, MMP-3, and IL-5.
Tubulin mRNA was used as a control (n = 4).
(C) Representative image of a 24-month-old p16-3MRmouse before (left) and after (right) GCV treatment. Luminescencewas quantified using a Xenogen Imaging
system.
(D–F) Fat biopsies from old (20–24months) or young (3–4months) p16-3MRmice, treated with PBS or GCV as described in (A). (D) Biopsies were incubated with a
coelentarazine solution and luminescence quantified using a Xenogen Imaging system. (E) Biopsies were fixed in formalin, stained at pH 6 with X-Gal solution to
measure SA-b-gal activity, and recorded using a photoscanner. (F) RNA was extracted from the biopsies and quantified by qRT-PCR for mRNA levels of
endogenous p16INK4a. Actin mRNA was used as a control (n = 4).
Data show are the mean ± SD. **p < 0.01; ***p < 0.001.
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p16INK4a- or p21-positive cells per se is not sufficient to delay
wound healing. These data indicate that senescent cells facili-
tate cutaneous wound repair and that their absence significantly
retards the kinetics of wound closure.
Senescent Endothelial andMesenchymal Cells Promote
Granulation Tissue Formation
To understand how senescent cells contribute to wound heal-
ing and closure, we analyzed the wounds by histology 6, 9,
and 15 days after injury. On day 6, the wounds of PBS-treated
mice showed significant wound contraction and marked re-
epithelialization. At this time, wounds of GCV-treated mice,
in contrast, showed wide epithelial and dermal edges and
the wound gap was filled with necrotic fibrinoid and cellular
debris, with much reduced angiogenesis and inflammation,
a paucity of collagen deposition, and poor formation of granu-
lation tissue as revealed by trichrome staining (Figures 4A
and 4B). Accordingly, GCV-treated wounds also showed a
paucity of fibroblasts and endothelial cells (Figure 4A), consis-
tent with impaired granulation tissue formation. Apoptosis was
only slightly but not significantly increased in the poorly formedDevelopmegranulation tissue (Figure S4A), most likely reflecting the death
of senescent cells and arguing against a significant bystander
effect of GCV.
By 9 days after injury, granulation tissue formation and angio-
genesis were similar between GCV- and vehicle-treated mice
(Figure S4B), confirming a requirement for senescent cells for
optimal kinetics of wound closure. However, 15 days after injury,
wounds harbored by GCV-treated mice were significantly more
fibrotic, as measured by collagen deposition and hydroxyproline
content (Figures S4C–S4E), in agreement with reports indicating
a role for senescent cells in limiting fibrosis in the skin and liver
(Jun and Lau, 2010; Krizhanovsky et al., 2008). Analysis of the
levels of mRNAs encoding different matrix metalloproteinases
revealed that wound biopsies had significantly less MMP-2 but
significantly more MMP-10 and MMP-13 when isolated from
mice treated with GCV compared with vehicle-treated mice (Fig-
ure S4F). Moreover, dermal mouse fibroblasts showed reduced
collagen production 6 days after we induced senescence by IR
(Figure S4G). Thus, the senescent cells in wounds likely secreted
less collagen and expressed higher levels of certain MMPs, sup-
porting our results with picrosirius red staining (Figure S4C) and a
role for senescent cells in limiting fibrosis.ntal Cell 31, 722–733, December 22, 2014 ª2014 Elsevier Inc. 725
Figure 3. Senescent Cells Are Induced and Necessary for Optimal Cutaneous Wound Healing
In all cases, mice were wounded using a 6 mm punch to dorsal skin and treated with PBS (vehicle control) or GCV (five daily i.p. injections) from 1 to 6 days after
injury (n = at least 4 mice per group).
(A and B) p16-3MR mice were wounded, injected i.p. with coelentarazine, and imaged with a Xenogen imaging system at the indicated times after injury. (A)
Quantification of the luminescence. (B) Typical images, both at the indicated time (days) after injury.
(C) Skin biopsies of p16-3MR mice were collected 6 days after injury, fixed, and stained for nuclei (DAPI; blue) or mRFP (immunostaining; red). White asterisks
define the wound edges.
(D–F) p16INK4a (D), mRFP (E), and p21 (F) mRNA levels were quantified by qRT-PCR from skin biopsies excised from PBS or GCV-treated wounds to p16-3MR
mice at the indicated intervals after injury. Actin was used to control for cDNA quantity.
(G) Wound sizes of WT or p16-3MR mice were measured at the indicated days after wounding.
(H) Representative image of wounds at the indicated days after injury of p16-3MR mice.
(I) Wound sizes of WT, p16 KO, p21 KO, and p16/p21 DKO mice were measured at the indicated days after wounding.
Data shown are the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.0001.
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wounding, we sorted the RFP+ population from skin biopsies
6 days after injury. Fluorescence-activated cell sorting analysis
showed that RFP+ cells comprised 2%–5% of the total cell
population dissociated from the tissue (data not shown) and
were senescent as determined by elevated expression of
p16INK4a, p21, and 3MR mRNAs, decreased expression of
lamin B1 mRNA (Figure 4C), and increased SA-b-gal positivity
(Figure S4H). Notably, RFP+ cells were positive for markers of
fibroblasts and endothelial cells (which were highly enriched726 Developmental Cell 31, 722–733, December 22, 2014 ª2014 Elsin the senescent population), but negative for keratinocyte
markers (Figure 4D), indicating that fibroblasts and endothelial
cells, but not the epidermal epithelial cells, are the predominant
cell types that become senescent in response to skin injury.
A fraction of senescent (RFP+) fibroblasts (2.8%) was also
positive for a marker of myofibroblasts (smooth muscle actin
[SMA]), as reported (Jun and Lau, 2010; Krizhanovsky et al.,
2008).
To detect senescent cells in wounds independently of the 3MR
transgene, we stained wound tissue for p21 (because, to date,evier Inc.
Figure 4. Characterization of Senescent Cells Induced during Wound Healing
(A) Longitudinal sections of wounds from PBS-treated (vehicle, left panels) and GCV-treated mice (right panels) (n = 8), collected 6 days after wounding, were
stained with H&E or specific antibodies and scored. Dermis is defined as D and epidermis as E. In the H&E staining, black and green arrows indicate the original
wound edges and re-epithelialized edges, respectively. Scale bars represent 500 mm. Sections were additionally stained with Masson’s trichrome (for collagen
fibers) or antibodies against SMA (marker for myofibroblast), vimentin (marker for mesenchymal cells), or factor VIII (marker for endothelial cells). Higher
magnification of the boxed areas is shown on the bottom to the right. Positive staining is indicated by arrows. Scale bars represent 100 mm for the main panel and
20 mm for the insets.
(B) Table shows the percentage of epithelialization after injury and histological scores for angiogenesis, granulation, and inflammation, based both on the staining
represented in (A).
(C and D) Cells from wounds collected 6 days after injury were isolated and sorted for RFP. mRNA levels encoding the indicated proteins were quantified by qRT-
PCR. Actin was used as a control for RNA quantity (n = 3 independent experiments).
(E) Sections described in (A) were immunostained for p21. Black arrows indicate positive fibroblasts, and green arrows indicate positive endothelium. Insets show
higher magnification of the section. Scale bars represent 200 mm for the main panel and 40 mm for the insets. Data shown are the mean ± SD. *p < 0.05, **p < 0.01,
***p < 0.0001.
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ably specific). The kinetics of p21 expression were similar to that
of p16INK4a and 3MR during wound closure (Figure 3F). Wound
gaps of control, but not GCV-treated, mice showed p21+ cells,Developmewhich were mostly fibroblasts and capillary endothelial cells
(based on morphology), confirming that senescent cells present
in the wounds are mostly mesenchymal/fibroblastic and endo-
thelial cells (Figure 4E).ntal Cell 31, 722–733, December 22, 2014 ª2014 Elsevier Inc. 727
Figure 5. PDGF-A Is Expressed and Secreted by Senescent Cells
(A) mRNA levels of the indicated proteins were quantified by qRT-PCR in cells sorted from wounds as described in Figure 4D. Actin was used to control for RNA
quantity (n = 3).
(B) Skin biopsies excised fromPBS- or GCV-treated wounds in p16-3MRmice were collected at the indicated intervals after injury, and PDGFAmRNA levels were
quantified by qRT-PCR. Actin was used to control for RNA quantity (n = 5).
(C) Skin biopsies of p16-3MR mice were collected 6 days after injury, fixed, stained with DAPI (blue; indicating nuclei), and immunostained for mRFP (red) and
PDGF-A (green).
(D) Cells were derived from wounds 6 days after injury and sorted for RFP. RFP+ cells were plated, fixed 24 hr later, and then stained with DAPI (blue) and
immunostained for PDGF-A (red) and vimentin (green, left panels) or factor VIII (green, right panels).
(E and F) Murine skin fibroblasts (SF) or endothelial cells (EC) were mock irradiated (NS) or made senescent by irradiation (SEN; 10 Gy X-ray). At 4 days after
irradiation, RNA and conditioned media were collected and analyzed for PDGF-A mRNA and secreted protein by qRT-PCR and ELISA, respectively (n = 4). Data
shown are the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.0001.
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Healing
To define potential mechanisms by which senescent cells stim-
ulate tissue repair, we isolated RFP+ cells from wounds 6 days
after injury andmeasured the levels of mRNAs encoding proteins
known to aid in wound healing. Compared with RFP cells, RFP+
cells expressed very high levels of PDGF-A, not previously iden-
tified as a SASP factor, and VEGF, a known SASP component
(Coppé et al., 2006) (Figure 5A). RFP+ cells also had moderately
elevated levels of the SASP factors PAI-1, CCL5, and CCL2,
but not other SASP factors, such as IL-6 or transforming growth
factor b (Figure 5A).
PDGF-A is expressed by several cell types during tissue repair
and is generally reduced in mice with impaired wound healing
(Beer et al., 1997). PDGF-A is also mitogenic for cells of
mesenchymal origin that express the receptor PDGF-Ra, plays728 Developmental Cell 31, 722–733, December 22, 2014 ª2014 Elsan important role in the formation of granulation tissue, and
is crucial for myofibroblast differentiation/maturation during
wound repair (Betsholtz, 2004; Boström et al., 1996; Ostman
and Heldin, 2001; Pho et al., 2008).
PDGFA, but notably not PDGFB, mRNA increased between
days 3 and 6 after wounding p16-3MR mice, and GCV strongly
reduced PDGFA expression (Figures 5B and S5A). PDGF-A+
cells were evident in the granulation tissue 6 days after wound-
ing and were also RFP+ (Figure 5C). In addition, RFP+ mesen-
chymal and endothelial cells isolated from the wounds of p16-
3MR animals were also PDGF-A+ (Figure 5D). Further, cultured
primary mouse skin fibroblasts and endothelial cells expressed
PDGFA, but not PDGFB, mRNA 4 days after they were induced
to senesce by IR (Figures 5E and S5B). These senescent cells
also secreted significantly higher levels of PDGF-AA, but not
PDGF-AB or PDGF-BB, relative to nonsenescent cells (Figuresevier Inc.
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pressed by the senescent cells that populate wounds. This
result was surprising because ectopic PDGF-BB, not PDGF-
AA, is used clinically to enhance wound healing (Doukas et al.,
2001).
In the 3–6 day interval after wounding, regardless of GCV treat-
ment, the classic SASP factor IL-6 was not expressed (data not
shown), although it was robustly induced 7–10 days after
cultured MEFs were stimulated to senesce by IR (Coppé et al.,
2008) (Figure S5E). In contrast, MEFs induced to senescence
by IR expressed high levels of PDGFA mRNA very early (2–
4 days) after the senescence stimulus (Figure S5E). These data
suggest the SASP is a dynamic phenotype and that it can have
different effects depending on the interval during which senes-
cent cells are present.
Senescence-Associated PDGF-A Promotes Optimal
Wound Closure through Myofibroblast Differentiation
The speed of wound closure depends largely on wound contrac-
tion during the proliferative phase of wound healing (Midwood
et al., 2004). This contraction is driven mainly by myofibroblasts,
which are thought to arise from the conversion of wound site fi-
broblasts into a myofibroblastic phenotype (Gabbiani, 2003).
Dermal fibroblasts isolated from p16-3MR mice and induced to
senescence by IR showed no change in contractile capacity
compared with nonsenescent fibroblasts, suggesting that se-
nescent cells do not act cell autonomously during wound healing
by directly contributing to contraction (Figure S6A). Notably,
GCV strongly decreased the number of myofibroblasts in the
midregion of p16-3MR wounds 6 days after injury (Figures 4A
and S6B), as reflected by reduced SMA expression (Figure S6C).
The paucity of myofibroblasts in senescence-free wounds was
confirmed by decreased levels of the mRNA encoding cofilin,
another marker of mature myofibroblasts (Figure S6D). Thus,
elimination of senescent cells by GCV depleted wound sites of
myofibroblasts, consistent with the slower wound healing shown
by GCV-treated p16-3MR mice. Importantly, wounds with or
without senescent cells showed comparable levels of Ki67+
cells, arguing against a major effect of GCV on cell proliferation
(data not shown).
Our findings suggest the PDGF-AA secreted by senescent fi-
broblasts and endothelial cells in wounded skin might optimize
wound healing by inducing myofibroblast differentiation. In sup-
port of this idea, treatment of nonsenescent murine skin fibro-
blasts and MEFs with conditioned media from senescent cells
increased the percentage of SMA-positive cells, similar to the
increase obtained by treating the cells with recombinant
PDGF-AA (Figures 6A and 6B; data not shown). This increase
was suppressed by a PDGF-A blocking antibody, confirming
that senescent cell-derived PDGF-AA was responsible for differ-
entiating nonsenescent fibroblasts into myofibroblasts (Figures
6A and 6B).
To determine the physiological consequence of PDGF-AA
secretion by senescent cells during wound healing, we topically
applied recombinant PDGF-AA to skin wounds on p16-3MR
mice in which senescent cells were eliminated by GCV. Strik-
ingly, PDGF-AA significantly increased the percentage of
SMA-positive myofibroblasts in the wounds (Figures 6C and
S6E) and completely restored the kinetics of wound closure toDevelopmethat of vehicle-treated mice (Figure 6D). Additionally, topical
administration of the PDGF antagonist PDGF-RA delayed
wound healing in the control mice, indicating that senescent
cell-derived PDGF-AA is necessary and sufficient for timely
wound closure in WT mice (Figure 6D). Wounds in p16-3MR
mice treated with both GCV and PDGF-AA showed insignifi-
cantly reduced collagen deposition compared with wounds in
PBS-treated mice (Figure S6F), suggesting that the increased
fibrosis in senescence-free wounds is not due to a lack of
PDGF-AA. As suggested by others, the increased fibrosis in
senescence-free wounds might be due in part to the paucity
of proteases secreted by senescent cells (Jun and Lau, 2010;
Krizhanovsky et al., 2008).
Similar to GCV-treated p16-3MR mice, wounds in p16/p21
DKO mice showed significantly fewer myofibroblasts after
wounding compared with WT mice (Figure S6G). Likewise,
gene expression profiling revealed lower PDGFA mRNA levels
in DKO tissues (Figure 6E), consistent with deficient myofibro-
blast differentiation and reduced granulation tissue formation.
Importantly, as observed in GCV-treated p16-3MR mice, topical
treatment with recombinant PDGF-AA rescued the delayed
wound healing kinetics of p16/p21 DKOmice (Figure 6F). Topical
PDGF-AA also had little effect on the fibrosis that developed af-
ter wounding p16/p21 DKO skin (Figure S6H).
Together, these findings identify PDGF-AA as an early SASP
factor produced by senescent cells in wound sites, which opti-
mizes myofibroblast differentiation and hence the kinetics of
wound closure.
DISCUSSION
Senescent cells accumulate with age and are thought to
contribute to age-related diseases through the SASP (Coppé
et al., 2008, 2010a; Krtolica et al., 2001; Parrinello et al., 2005).
These deleterious effects do not explain why the cell nonauton-
omous phenotype of senescent cells was selected during evolu-
tion. However, recent reports showed a beneficial role for the
SASP during embryonic development (Muñoz-Espı́n et al.,
2013; Storer et al., 2013) and a role in limiting fibrosis after tissue
injury (Jun and Lau, 2010; Krizhanovsky et al., 2008).
Our findings identify a positive effect of senescent cells and
the SASP: the ability to accelerate cutaneous wound healing
through the early secretion of the SASP factor PDGF-AA. Our
data indicate that wounding induces senescence in resident fi-
broblasts and primarily endothelial cells. This senescence induc-
tion entailed the secretion of PDGF-AA by the senescent cells,
which promotes myofibroblast differentiation, optimal granula-
tion tissue formation, and ultimately the kinetics of wound
closure.
The upstream signals that induce senescence after wounding
are not yet known, although activation of the matricellular pro-
tein CCN1 was shown to induce senescence during skin and
liver repair (Jun and Lau, 2010; Kim et al., 2013). Interestingly,
CCN1 induced PDGF-A in primary cells in culture, but it
also induced IL-6, a prominent late-appearing SASP factor
that we failed to identify as part of the senescence-associated
repair program, at least during the transient appearance of
senescent cells during wound healing (M.D. and J.C., unpub-
lished data). Thus, CCN1 might only partially account for thental Cell 31, 722–733, December 22, 2014 ª2014 Elsevier Inc. 729
Figure 6. Senescence-Associated PDGF-A Drives Myofibroblast Differentiation
(A and B) Skin fibroblasts were incubated with conditioned media from IR-induced senescent (CM SEN) or nonsenescent (CM NS) cells containing nonspecific
rabbit IgG or a PDGF-A blocking antibody; after 48 hr, the cells were immunostained for SMA (green), and nuclei were stained with DAPI (blue). Ten ng/ml re-
combinant PDGF-AA was used as a positive control. (A) Representative image. (B) Percentage of SMA-positive cells relative to the total (DAPI positive) number of
cells (n = 6).
(C and D) Wound healing was performed as described in Figure 3G, except PDGF-AA (20 ng) or vehicle (PBS) were topically applied daily from 1 to 6 d after
wounding (n = 5). (C) Biopsies from wounds 6 days after injury were embedded in paraffin and stained for SMA. The graph shows the percentage of positive cells
present in the wound gap. (D) Wound sizes were measured at the indicated times after injury. In addition to the groups described, a cohort of control p16-3MR
mice was treated with PDGF-RA (daily topical application of 20 ng from 1 to 6 days after injury).
(E) RNAwas isolated fromwounded areas 6 days after injury of WT and p16/p21 DKOmice. PDGFAmRNA levels were quantified by qRT-PCR. Actin was used to
control for RNA quantity (n = 3).
(F) Wound healing was performed and measured as described in (B). PDGF-AA (20 ng) or vehicle (PBS) were topically applied daily from 1 to 6 days after
wounding (n = 3). Data shown are the mean ± SD. **p < 0.01, ***p < 0.0001.
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and Lau, 2010; Krizhanovsky et al., 2008), we also found that
the presence of senescent cells restrains fibrosis. While topical
PDGF-AA compensated for the absence of senescent cells in
GCV-treated p16-3MR and p16/p21 DKO mice with respect to
the kinetics of wound closure, it did little to resolve the excess
fibrosis, which is likely due to the absence of proteases that
comprise the SASP.
In contrast to the well-documented deleterious effects of se-
nescent cells and the SASP, the results presented here unam-
biguously demonstrate a positive role for senescent cells and
the SASP in tissue repair. Notably, senescent cells were present
only transiently during tissue repair, in contrast to the persistent
presence of senescent cells in aged or chronically damaged tis-
sues. Moreover, PDGF-A was induced very early upon senes-
cence induction in cell culture, suggesting the time-dependent
regulation of SASP factors might in part explain the beneficial
versus deleterious effects of senescent cells. As such, our find-
ings, together with several recent reports, help explain the evolu-
tionary forces that shaped the complex senescence response.730 Developmental Cell 31, 722–733, December 22, 2014 ª2014 ElsFuture efforts are needed to determine possible differences
among senescence inducers in consequent gene expression
and protein secretion to better understand the dichotomy of
how senescent phenotypes exert their effects in vivo.
EXPERIMENTAL PROCEDURES
Mice
p16-3MRmice (see Supplemental Experimental Procedures) were maintained
in the AALAC-accredited Buck Institute for Research on Aging animal facility.
All procedures were approved by the Institutional Animal Care and Use Com-
mittee. p16-3MR mice were bred in house.
For IR-induced senescence, 8-week-old p16-3MRmice were X irradiated (7
Gy) and treated 90 days later with vehicle or GCV. GCV was administered via
daily intraperitoneal (i.p.) injections for 5 consecutive days at 25 mg/kg in PBS.
Control mice were injected with an equal volume of PBS.
For wound healing, two equal-sized wounds were created on dorsal skin by
a 6 mm punch. Treatment with GCV, PBS, recombinant PDGF-AA (BioVision;
20 ng topical applications), and PDGF-RA blocking peptide (Santa Cruz; 20 ng
topical applications) were performed daily for 5 consecutive days before
wounding or for 5 days starting 1 day after injury. Wound sizes were measured
using a caliper.evier Inc.
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Day 13.5 embryos were dissected and cultured to produce MEFs, as
described (Demaria et al., 2010). Skin fibroblasts were derived from the dorsal
skin of 2- to 3-month-old mice, as described (Seluanov et al., 2010). Primary
skin microvascular endothelial cells were purchased from Cellbiologics (Cata-
log No.: C57-6064) and cultured according to the manufacturer’s protocol. For
IR-induced senescence, cells were cultured to confluence, exposed to 10 Gy
X-rays, and analyzed 7, 10, or 15 days later; control cells weremock irradiated.
For CCN1 treatments, recombinant protein (a gift from the Lester Lau labora-
tory) was diluted 1:20 in serum-containing medium and administered to cells
for 3 days. Senescence was confirmed by bromodeoxyuridine labeling and
SA-bgal activity (Dimri et al., 1995) using commercial kits (Life Technologies
and BioVision). Control and senescent cells were treated with the indicated
concentrations of GCV for 6 days; the medium was refreshed every 2 days.
Cell viability was assessed using the MTS assay (Promega) according to the
manufacturer’s protocol.
Bioluminescence
For cell culture experiments, a Renilla Luciferase Assay System (Promega) was
used according to the manufacturer’s protocol; luminescence intensity was
measured with a luminometer. For in vivo luminescence, mice were injected
i.p. with 15 mg of Xenolight RediJect Coelentarazine h (Calipers). At 25 min
later, the mice were anesthetized with isofluorane, and luminescence was
measured with a Xenogen IVIS-200 Optical in vivo imaging System (Caliper
Life Sciences; 5 min medium binning).
Immunoblot Analysis
Cells were washed with warm PBS, lysed, and subjected to SDS-PAGE
using 4%-12% Bis-Tris gels; separated proteins were transferred to
polyvinylidene fluoride membranes (Freund et al., 2012). Membranes were
blocked and incubated overnight at 4C with antirabbit primary antibodies
(Santa Cruz Biotechnology for p16INK4a, actin, and tubulin; Abcam for
SMA). Membranes were washed and incubated with horseradish peroxi-
dase-conjugated (1:5,000; Cell Signaling) secondary antibodies for 45 min
at room temperature and washed again. Signals were detected by enhanced
chemiluminescence.
Real-Time PCR
Total RNA was prepared using the PureLink Micro-to-Midi total RNA Purifica-
tion System (Life Technologies). RNAwas reverse transcribed into cDNA using
a kit (Applied Biosystems). Quantitative RT-PCR (qRT-PCR) reactions were
performed as described (Demaria et al., 2010) using the Universal Probe
Library system (Roche). TheACTIN predeveloped TaqMan assay (Applied Bio-
systems) was used to control for cDNA quantity. See Supplemental Informa-
tion for a list of primers.
Enzyme-Linked Immunosorbent Assays, Conditioned Media, and
Myofibroblast Differentiation
ELISA kits to detect PDGF-AA, PDGF-AB, and PDGF-BB were from R&D Sys-
tems and used according to the manufacturer’s protocols. Conditioned media
were prepared by washing cells with serum-free Dulbecco’s modified Eagle’s
medium (DMEM) and incubating in serum-free DMEM for 24 hr. ELISA results
were normalized to cell number. For myofibroblast differentiation, conditioned
media were supplemented with 2% fetal bovine serum before treating cells
with blocking antibody against PDGF-A (200 ng/ml) or rabbit IgG (Santa
Cruz Biotechnology). Recombinant PDGF-AA (20 ng/ml) was used as positive
control.
Histology
Formalin-fixed skin wound specimens were trimmed longitudinally along the
wound center at the widest part of the wound (largest diameter area). Trimmed
sections were processed, embedded in paraffin, blocked, sectioned, and
stained with hematoxylin and eosin (H&E) and/or Masson’s trichrome. Stained
sections were examined histologically.
Immunofluorescence
Cells or paraffin-embedded skin biopsies on glass coverslips were washed in
PBS, fixed in 4% paraformaldehyde, quenched with 50 mM ammonium chlo-Developmeride, permeabilized with 0.3% Triton X-100 in PBS, saturated with 3% goat
serum (Life Technologies), and incubatedwith primary antibodies at room tem-
perature (Abcam, SMA; Santa Cruz, PDGF-A; Allele Biotechnology, mRFP) for
1 hr, followed by Alexa fluorescein-labeled secondary antibodies (Life Tech-
nologies) and Prolong Fade with 40,6-diamidino-2-phenylindole (DAPI) (Life
Technologies). Images were quantified using ImageJ (http://imagej.nih.gov/
ij/) and Cell Profiler (www.cellprofiler.org).
Immunohistochemistry
Sections were deparaffinized and rehydrated and then rinsed in 13 Tris-buff-
ered saline (TBS) for 10min. Sections weremicrowaved in 10mMcitrate buffer
for 5 min at 40% power in a 1,100 W oven and left to cool for 20 min. After a
10 min wash in 1 3 TBS, endogenous peroxidase activity was blocked with
0.5% H2O2 in 1 3 TBS for 10 min; 10% normal goat serum was applied for
1 hr, and then VIMENTIN (Santa Cruz, at 1:30 dilution), FACTOR VIII (Deko,
at 1:500), p21 (Santa Cruz, at 1:400), TUNEL (Millipore, at 1:300), and SMA an-
tibodies (Abcam, at 1:100 in 1% bovine serum albumin [BSA]) were applied
overnight. Sections were washed, incubated for 1 hr in biotinylated antirabbit
antibody, diluted in 1% BSA in TBS (Vector Labs BA-1000 at 1:200), and then
for 30 min with Vectastain Elite ABC reagent. Sections were washed and incu-
bated using a 3,30-diaminobenzidine (DAB) substrate kit for 4 min (Vector SK
4100). Sections were counterstained with hematoxylin and dehydrated. Slides
were imaged using a Nikon E800 microscope. Hematoxylin and DAB staining
were separated into two images using ImageJ Fiji and cells were counted using
IMARIS spot count.
Picrosirius Red Staining
Paraffin sections of skin biopsies were dewaxed and hydrated. Nuclei were
stained with Weigert’s hematoxylin for 8 min, and slides were washed for
10 min in running water and stained with picrosirius red solution for 1 hr
(0.5 g Sirius Red, 500 ml saturated aqueous picric acid solution; Sigma-Al-
drich). Slides were washed, dehydrated in 100% ethanol, cleared in xylene,
and mounted in a resinous medium. Slides were examined through cross-
polarized and bright field light, and positive areas were calculated using
ImageJ.
SA-b-Gal Assay
Skin biopsies were flash frozen in Optimal Cutting Temperature (OCT) and
10 mm sections cut. Immediately after sectioning, samples were fixed and
stained overnight with an X-Gal solution using a commercial kit (Biovision).
Samples were then mounted using Prolong with DAPI. Images were acquired
at 2003 and 4003 magnification, and the negative pictures of the SA-b-gal
staining and DAPI images were merged.
Hydroxyproline
Skin samples were collected 15 days after wounding, and conditioned media
were collected after 24 hr of culture. Samples were analyzed using a commer-
cial assay kit (Biovision). Briefly, 10 mg of tissue or 100 ml of conditioned media
were hydrolyzed at 120C for 3 hr, and 10 ml of each sample was evaporated to
dryness and processed for optical density measurements using a colorimeter
(560 nm).
Contraction Assay
Control or irradiated skin fibroblasts (1.5 3 105) were plated on a 3D collagen
matrix in 24-well plates (Cell Biolabs). At 48 hr later, the matrix was detached
from the wells with a spatula; 2 hr later, contraction determined by measuring
the diameter of the matrix using a ruler.
Statistical Analysis
An unpaired t test was used to calculate a p value for pairwise comparisons; p
values on multiple comparisons were calculated using two-way ANOVA with
Bonferroni posttest.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.devcel.2014.11.012.ntal Cell 31, 722–733, December 22, 2014 ª2014 Elsevier Inc. 731
Developmental Cell
Cellular Senescence, Wound Healing, and PDGF-AAACKNOWLEDGMENTS
We thank Cathy Vitelli, Shannon O’Hara, and Taki Te Koi for the help with his-
tology, cell sorting, and imaging and Sanjiv Gambhir (Stanford University) for
the 3MR construct. This work was supported by grants from the American Ital-
ian Cancer Foundation (M.D.), the Japan Science and Technology Agency
(Presto to N.O. and Crest to E.H.), the U.S. NIH (AG017242 to H.V.S., J.C.,
J.H., J.V., M.E.T.D.; AG009909, AG041122, and CA166347 to J.C.), and a Eu-
ropean Council Advanced Grant (GA233424 to J.H.).
Received: June 12, 2014
Revised: October 7, 2014
Accepted: November 10, 2014
Published: December 11, 2014
REFERENCES
Baker, D.J., Wijshake, T., Tchkonia, T., LeBrasseur, N.K., Childs, B.G., van de
Sluis, B., Kirkland, J.L., and van Deursen, J.M. (2011). Clearance of p16Ink4a-
positive senescent cells delays ageing-associated disorders. Nature 479,
232–236.
Beer, H.D., Longaker, M.T., and Werner, S. (1997). Reduced expression of
PDGF and PDGF receptors during impaired wound healing. J. Invest.
Dermatol. 109, 132–138.
Betsholtz, C. (2004). Insight into the physiological functions of PDGF through
genetic studies in mice. Cytokine Growth Factor Rev. 15, 215–228.
Boström, H., Willetts, K., Pekny, M., Levéen, P., Lindahl, P., Hedstrand, H.,
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